3rd Diabetes Partnering and Deal-making
Conference - Boston, MA, USA
With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?
GTC’s 3rd Diabetes Partnering and Deal Making Conference, part of the 3rd Diabetes Summit, is a partnering and business development conference that gives companies an opportunity to network with high-level executives and explore potential collaborations, learn about relevant issues and deals that will affect the industry. This important meeting will be held on April 29-30, 2013 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss business strategies and opportunities under the current regulatory landscape.
(Courtesy of Hyatt Regency, via starthereboston.com)
3rd Diabetes Partnering and Deal-making
Apr 29, 2013 to Apr 30, 2013
Hyatt Regency, 1 Ave De Lafayette, Boston, MA, USA
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
